{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:03:06Z","timestamp":1792609386936,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bmc.2019.115209","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T11:16:05Z","timestamp":1573298165000},"page":"115209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["High content phenotypic screening identifies serotonin receptor modulators with selective activity upon breast cancer cell cycle and cytokine signaling pathways"],"prefix":"10.1016","volume":"28","author":[{"given":"Scott J.","family":"Warchal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison F.","family":"Munro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraff","family":"Makda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil O.","family":"Carragher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2019.115209_b0005","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.drudis.2015.10.008","article-title":"Next-generation sequencing and empowering personalised cancer medicine","volume":"20","author":"McDermott","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2019.115209_b0010","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/14737159.2014.916213","article-title":"Next-generation sequencing in precision oncology: challenges and opportunities","volume":"14","author":"Kruglyak","year":"2014","journal-title":"Exp Rev Mol Diagn"},{"key":"10.1016\/j.bmc.2019.115209_b0015","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2019.115209_b0020","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2019.115209_b0025","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bmc.2019.115209_b0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2019.115209_b0035","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2019.115209_b0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrc2820","article-title":"Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents","volume":"10","author":"Sharma","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2019.115209_b0045","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2016.175","article-title":"Screening out irrelevant cell-based models of disease","volume":"15","author":"Horvath","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2019.115209_b0050","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2019.115209_b0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2019.115209_b0060","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ygyno.2016.12.016","article-title":"Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells","volume":"144","author":"Haltia","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bmc.2019.115209_b0065","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12885-016-2452-5","article-title":"Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer","volume":"16","author":"Kangaspeska","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bmc.2019.115209_b0070","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.31","article-title":"Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia","volume":"5","author":"Eriksson","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bmc.2019.115209_b0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nchembio.1986","article-title":"Correlating chemical sensitivity and basal gene expression reveals mechanism of action","volume":"12","author":"Rees","year":"2016","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2019.115209_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046518","article-title":"Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection","volume":"7","author":"Kwei","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2019.115209_b0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ygeno.2008.08.002","article-title":"In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer","volume":"93","author":"Jung","year":"2009","journal-title":"Genomics"},{"key":"10.1016\/j.bmc.2019.115209_b0090","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.bmc.2019.115209_b0095","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1016\/S2352-3026(17)30208-9","article-title":"Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study","volume":"4","author":"Snijder","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bmc.2019.115209_b0100","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/1535-7163.MCT-09-1148","article-title":"High-content phenotypic profiling of drug response signatures across distinct cancer cells","volume":"9","author":"Caie","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2019.115209_b0105","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/nprot.2016.105","article-title":"Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes","volume":"11","author":"Bray","year":"2016","journal-title":"Nat Protoc"},{"key":"10.1016\/j.bmc.2019.115209_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/gigascience\/giw014","article-title":"A dataset of images and morphological profiles of 30 000 small-molecule treatments using the Cell Painting assay","volume":"6","author":"Bray","year":"2017","journal-title":"GigaScience"},{"key":"10.1016\/j.bmc.2019.115209_b0115","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1126\/science.1100709","article-title":"Multidimensional drug profiling by automated microscopy","volume":"306","author":"Perlman","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bmc.2019.115209_b0120","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nmeth.1984","article-title":"An image analysis toolbox for high-throughput C. elegans assays","volume":"9","author":"Wahlby","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.bmc.2019.115209_b0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-4939-7847-2_13","article-title":"High-dimensional profiling: the theta comparative cell scoring method","volume":"1787","author":"Warchal","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bmc.2019.115209_b0130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/adt.2016.730","article-title":"Development of the Theta comparative cell scoring method to quantify diverse phenotypic responses between distinct cell types","volume":"14","author":"Warchal","year":"2016","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.bmc.2019.115209_b0135","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"Cell Profiler: image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol"},{"key":"10.1016\/j.bmc.2019.115209_b0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"N. Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2019.115209_b0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmc.2019.115209_b0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1087057109351311","article-title":"Integration of multiple readouts into the z' factor for assay quality assessment","volume":"15","author":"Kummel","year":"2010","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.bmc.2019.115209_b0155","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biochi.2018.06.016","article-title":"Serotonin and human cancer: a critical view","volume":"161","author":"Sarrouilhe","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.bmc.2019.115209_b0160","first-page":"243","article-title":"5-HT serotonin receptors modulate mitogenic signaling and impact tumor cell viability","volume":"9","author":"Ballou","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.bmc.2019.115209_b0165","first-page":"363","article-title":"Expression and localization of serotonin receptors in human breast cancer","volume":"33","author":"Kopparapu","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bmc.2019.115209_b0170","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1186\/bcr2448","article-title":"Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival","volume":"11","author":"Pai","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.bmc.2019.115209_b0175","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3389\/fimmu.2018.01999","article-title":"Structure of TRAF Family: current understanding of receptor recognition","volume":"9","author":"Park","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2019.115209_b0180","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1534-5807(04)00022-X","article-title":"Serotonin regulates mammary gland development via an autocrine-paracrine loop","volume":"6","author":"Matsuda","year":"2004","journal-title":"Dev Cell"},{"key":"10.1016\/j.bmc.2019.115209_b0185","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1741-7015-8-90","article-title":"A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: the impact of duration of use, cumulative dose and latency","volume":"8","author":"Ashbury","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.bmc.2019.115209_b0190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/02841860903575273","article-title":"Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen","volume":"49","author":"Lash","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.bmc.2019.115209_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c693","article-title":"Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study","volume":"340","author":"Kelly","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.bmc.2019.115209_b0200","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/pon.4048","article-title":"A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients","volume":"25","author":"Sanjida","year":"2016","journal-title":"Psychooncology"},{"key":"10.1016\/j.bmc.2019.115209_b0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.febslet.2004.07.055","article-title":"Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments","volume":"573","author":"Breitling","year":"2004","journal-title":"FEBS Lett"},{"issue":"13","key":"10.1016\/j.bmc.2019.115209_b0210","first-page":"11","article-title":"Biological network exploration with Cytoscape 3","volume":"8","author":"Su","year":"2014","journal-title":"Curr Protoc Bioinform."},{"key":"10.1016\/j.bmc.2019.115209_b0215","doi-asserted-by":"crossref","first-page":"W60","DOI":"10.1093\/nar\/gky311","article-title":"GeneMANIA update 2018","volume":"46","author":"Franz","year":"2018","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.bmc.2019.115209_b0220","doi-asserted-by":"crossref","first-page":"D330","DOI":"10.1093\/nar\/gky1055","article-title":"The gene ontology resource: 20 years and still GOing strong","volume":"47","author":"C. The Gene Ontology","year":"2019","journal-title":"Nucl Acids Res"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619310521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619310521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:08:26Z","timestamp":1760836106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089619310521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0968089619310521"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115209","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High content phenotypic screening identifies serotonin receptor modulators with selective activity upon breast cancer cell cycle and cytokine signaling pathways","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115209"}}